Biogen (BIIB) Research & Development (2009 - 2026)

Biogen (BIIB) has reported Research & Development for 18 consecutive years, with $539.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 24.16% year-over-year to $539.0 million; the TTM figure through Mar 2026 stood at $1.9 billion (down 4.34% YoY), while the FY2025 annual figure was $1.8 billion, down 10.19% from the prior year.
• Research & Development came in at $539.0 million for Q1 2026 at Biogen, up from $509.4 million in the prior quarter.
• The five-year high for Research & Development was $736.3 million in Q3 2023, with the low at $75.0 million in Q4 2023.
• Average Research & Development over 5 years is $499.7 million, with a median of $516.2 million recorded in 2024.
• Across the five-year window, Research & Development sank 87.53% in 2023 and jumped 584.4% in 2024, its largest moves.
• Year by year, Research & Development stood at $601.6 million in 2022, then tumbled by 87.53% to $75.0 million in 2023, then surged by 584.4% to $513.3 million in 2024, then decreased by 0.76% to $509.4 million in 2025, then grew by 5.81% to $539.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $539.0 million, $509.4 million, and $436.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.